Objective To examine the association of Khorana score and the thrombosis risk in Ⅳ stage pancreatic cancer. Methods Tumor types,WBC,HB,PLT,BMI of 97 Ⅳ stage pancreatic cancer patients were measured and Khorana scores were calculated. Then the rela-tionship between Khorana scores and the thrombosis risk,overall survivals (OS)was analyzed. Results Thrombosis risk existed in patients with Ⅳ stage pancreatic cancer. Twenty-four patients had intermediate risk and their Khorana score was 1-2,Six of them (25.0％)had deep ve-nous thrombosis. Seventy-three patients (73.3％)had high risk and their Khorana score was 3 or more. Thirty-one of them (42.4％)had deep venous thrombosis,and had the higher rate than intermediate risk group. The OS of intermediate risk group was (11.92±0.27)month. The high risk group was (6.88±0.17)month,which was significantly lower than the intermediate risk group (P<0.01). Conclusion Khorana score can reflect the thrombosis risk. It is an index of judging the prognosis of patients with stage Ⅳ pancreatic cancer,and the abnormal increase prompts poor prognosis of patients.%目的 探讨Ⅳ期胰腺癌患者Khorana评分与患者血栓风险的相关性.方法 回顾性分析首都医科大学附属北京友谊医院2012年1月至2017年1月收治的Ⅳ期胰腺癌患者97例,分析根据肿瘤类型、白细胞、血小板、血红蛋白、体重指数(BMI)计算的Khorana评分与血栓风险及总生存时间的关系.结果 Ⅳ期胰腺癌患者普遍存在不同程度的血栓风险.Khorana评分中危组(1～2分,24例)患者发生深静脉血栓6例,占25.0％;Khorana评分高危组(评分≧3分,73例)患者发生深静脉血栓31例,占42.4％,显著高于中危组(P<0.05).Khorana评分中危组患者的生存期为(11.92±0.27)个月,Khorana评分高危组患者的生存期为(6.88±0.17)个月,显著低于中危组(P<0.01).结论 Khorana评分可以有效预测Ⅳ期胰腺癌患者的肿瘤高凝状态,其异常升高提示患者预后较差.
展开▼
